Skip To Main Content
Cecile Edith Vicier on Muck Rack

Cecile Edith Vicier

As seen in: ONCOLOGY journal, European Journal of Cancer
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Cecile Edith

Contact Cecile Edith, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

82 Efficacy, Safety, and Biomarker Analysis of ICARUS-BREAST01: A Phase 2 Study of Patritumab Deruxtecan (HER3-DXd) in Patients With HR+/HER2- Advanced Breast Cancer

|
By Livia Pierotti, Magali Lacroix-Triki, Cecile Edith Vicier, Jean-Sébastien Frenel
| ONCOLOGY journal Verified
Background Despite the improved clinical outcomes achieved with endocrine therapy (ET) plus CDK4/6 inhibitors (CDK4/6i) in hormone receptor–positive/ HER2-negative (HR+/HER2–) advanced breast cancer, few effective therapeutic agents are available beyond progression. HER3 expression is associated with poor prognosis and resistance to PI3K/AKT/mTOR inhibitors and ET.
Open in Who Shared Issue with article?

TAKTIC: A prospective, multicentre, uncontrolled, phase IB/II study of LY2780301, a p70S6K/AKT inhibitor, in combination with weekly paclitaxel in HER2-negative advanced breast cancer patients

|
By Cecile Edith Vicier, Institut Paoli-Calmettes, Aix-Marseille Univ, Patrick Sfumato
| European Journal of Cancer Verified
Highlights • LY2780301 (LY) is a dual AKT/S6 inhibitor. • This phase I/II trial aimed to evaluate LY in combo with weekly paclitaxel in HER2− ABC. • Combining LY2780301 + weekly paclitaxel was feasible and safe. • Antitumour activity was observed independently of PI3K/AKT pathway activation. Abstract Background Hormone-resistant HER2-negative or triple-negative advanced breast cancers (ABC) are routinely treated with paclitaxel chemotherapy.
Open in Who Shared Issue with article?

Rapalog-Mediated Repression of Tribbles Pseudokinase 3 Regulates Pre-mRNA Splicing

|
By Bojana Stefanovska, Gustave Roussy, Université Paris Sud, Cecile Edith Vicier
| cancerres.aacrjournals.org
Molecular Cell Biology Bojana Stefanovska, Cecile Edith Vicier, Thibault Dayris, Vasily Ogryzko, Veronique Scott, Ibrahim Bouakka, Suzette Delaloge, Anna Rocca, Olivia Le Saux, Olivier Trédan, Thomas Bachelot, Fabrice André and Olivia Fromigué DOI: 10.1158/0008-5472.CAN-19-2366 Published June 2020 This article requires a subscription to view the full text. You may purchase access to this article or login to access your subscription using the links below.
Open in Who Shared Issue with article?
See all 4 articles